The U.S. Centers for Medicare and Medicaid Services (CMS) said on Monday that it would announce a list of 15 drugs eligible for a third round of Medicare price negotiations by early February next year.

Conflicting QSSD definitions from two federal agencies mean that CMS’ administrative authority on drug pricing and payment is not well aligned with FDA’s authority to regulate drug safety and efficacy.